Overview:
The landscape of non–small cell lung cancer (NSCLC) treatment has been significantly altered by the introduction of immunotherapy and targeted agents. Despite these advancements, a considerable number of NSCLC patients fail to derive benefits from current therapeutic approaches, highlighting an existing medical gap. Additionally, even among those who do respond to immunotherapy or targeted agents, relapse remains a common occurrence. To address these challenges, there is a pressing need for novel mechanisms of action in subsequent lines of therapy. Promisingly, ongoing research explores new agents, such as antibody-drug conjugates targeting TROP2, with potential applications in various treatment settings for NSCLC. These novel agents not only offer potential improvements for newly diagnosed patients, but they also present additional options for those progressing on initial treatment regimens.
This interactive, “fireside chat-style” hybrid session will provide a comprehensive overview on the advent of TROP2-directed antibody drug conjugates in lung cancer treatment. The program will encourage discussion among experts and learners at the 21st Annual Winter Lung Cancer Conference®.
The in-person session is included in the 21st Annual Winter Lung Cancer Conference® registration. Please register here to attend virtually.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Describe the mechanistic rationale of TROP2-directed ADCs in the context of unmet clinical needs for patients with lung cancer.
- Review the efficacy and safety results from lung cancer clinical trials evaluating ADCs targeting TROP2.
- Apply recent evidence of TROP2-directed ADCs to patients with lung cancer across multiple lines of care.
Benjamin Levy, MD
Associate Professor of Oncology, Johns Hopkins University School of Medicine
Clinical Director of Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Washington, DC
Christine M. Lovly, MD, PhD
Associate Professor of Medicine, Division of Hematology-Oncology
Ingram Associate Professor of Cancer Research
Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center
Nashville, TN
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.5 Contact Hour.